[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"MSD Italia S.r.l.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":96},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100586501","burden-of-cytomegalovirus-reactivation-in-pediatric-patients-after-allogeneic-hematopoietic-stem-cell-transplantation-100586501",false,"NCT06916195","Burden of Cytomegalovirus Reactivation in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplantation","CMV PED Study - A Retrospective Observational Study To Understand The Clinical And Economic Burden Associated With Cytomegalovirus Reactivation and Related Health Outcomes In Pediatric Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation In Italy","CMV PED","Inclusion Criteria:\n\n* Patients from birth to less than 18 years of age (at the moment of the allogeneic HSCT);\n* Patients who received allogeneic HSCT between January 2018 and June 2020;\n* Patients (or their legally acceptable representatives) must have signed and dated the Informed Consent \\& Privacy Form (ICF), if applicable.\n\nExclusion Criteria:\n\n* Letermovir use at any time","ALL","0 Years","18 Years",{"count":21,"type":22},230,"ESTIMATED","OBSERVATIONAL","This observational retrospective analysis will provide useful information for clinicians and payers, and local guidelines committee members, to improve the understanding of Cytomegalovirus clinical and economic burden and clinical management of pediatric patients undergoing allogeneic Hematopoietic Stem Cells Transplantation in Italy.",[26,27],"Cytomegalovirus Infection","Hematopoietic Stem Cells Transplantation","RECRUITING","2026-03-31",{"date":31,"type":32},"2026-04-06","ACTUAL",{"date":34,"type":32},"2025-05-09",{"date":36,"type":22},"2026-07-15",{"name":38,"class":39},"MSD Italia S.r.l.","INDUSTRY",5,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":19,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100575354","study-on-disease-characteristics-and-treatment-in-locally-advanced-or-recurrent--metastatic-cervical-cancer-in-italy-100575354","NCT06771193","Study on Disease Characteristics and Treatment in Locally Advanced or Recurrent \u002F Metastatic Cervical Cancer in Italy","RETRACE Study - Retrospective Observational Study Evaluating Disease Characteristics and Treatment Landscape of High-risk Locally Advanced (LA) or Recurrent \u002F Metastatic (R\u002FM) Cervical Cancer in Italy","RETRACE","Inclusion Criteria:\n\n* Patient (or their legally acceptable representatives) must have signed and dated the Informed Consent \\& Privacy Form (ICF)\n* Age ≥18 years\n* Diagnosis of a cervical cancer\n* Locally advanced stage (not suitable for curative surgery) or recurrent or metastatic disease\n* Any treatment received between January 2018 and December 2021 for advanced disease\n\nExclusion Criteria:\n\n* Patients participating in a pharmacological clinical trial for the treatment of advanced disease\n* Patients who participated in a clinical trial\n* Patients who were administered with Pembrolizumab, Olaparib or Levantinib or medications from these class of drugs","FEMALE",{"count":51,"type":22},200,"Multicenter, Observational, Retrospective charts review. Observational study with descriptive purpose only. Retrospective data capture in consecutive patients diagnosed with CC who attended the Oncologic Clinics from Jan 2018 to Dec 2021 (using medical records, either electronic or not), inserted in eCRF and analyzed.",[54,55,56,57],"Cervical Cancer","Locally Advanced Cervical Cancer","Recurrent Cervical Cancer","Metastatic Cervical Cancer","2025-07-16",{"date":60,"type":32},"2025-07-20",{"date":62,"type":32},"2024-12-17",{"date":64,"type":22},"2025-12",{"name":38,"class":39},11,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":76,"conditions":77,"keywords":82,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100551999","a-study-to-describe-the-diagnostic-and-therapeutic-path-of-patients-with-nsclc-in-early-stage-and-locally-advanced-100551999","NCT06467383","A Study to Describe the Diagnostic and Therapeutic Path of Patients with NSCLC in Early Stage and Locally Advanced","Key-Early","Inclusion Criteria:\n\n1. Patients with stage I-III NSCLC who have received curative surgery or radiotherapy between January 2018 and June 2019 with available follow-up through January 2021\n2. Adult patients (aged ≥ 18 years) at the moment of diagnosis\n3. Patients (or their legally acceptable representatives) must have signed and dated the Informed Consent form; privacy Form (ICF). In case of deceased or untraceable patient the investigator before collecting data shall demonstrate and report all necessary measures adopted to contact the patient.\n\nExclusion Criteria:\n\n1. Patients without availability of medical charts or information required\n2. Enrollment in studies imposing a specific patient's management strategy which does not correspond to the site's normal clinical practice.",{"count":75,"type":22},600,"This is a non-interventional, retrospective observational study to improve knowledge regarding the diagnosis and treatments of patients who have\u002Fhad non-small cell lung cancer (NSCLC), either early stage (stage I-II).",[78,79,80,81],"Non-small Cell Lung Cancer","NSCLC","NSCLC, Stage III","NSCLC, Stage I",[83,84,85,86],"NSCLC early stage","NSCLC locally advanced","retrospective observational study","Real-World Evidence","2025-01-13",{"date":89,"type":32},"2025-01-14",{"date":91,"type":32},"2024-06-25",{"date":93,"type":22},"2025-06-24",{"name":38,"class":39},25,""]